Ads by Google
To accelerate the translation of basic discoveries about HIV into advances in vaccine design and evaluation, NIAID has formed a new Vaccine Discovery Branch within the Vaccine Research Program in the Division of AIDS.
New York City health department plans an initiative to give free HIV tests to everyone living in Bronx. This decision comes right on time as yesterday reports came out that New York residents have the highest rate of practicing unsafe sex.
Since 2003, US through the President's Emergency Plan for AIDS Relief has "extended a helping hand to" HIV-positive people living outside the country.
The Latino HIV Task Force, a group of health agencies and community organizations, will offer free HIV testing June 27 as part of the annual National HIV Testing Day. The task force will provide tests from 10 a.m. to 6 p.m. at the Southwest Multi-Service Center, 6400 High Star.
Hispanics in Houston and Harris County represent 21 percent of the 15,275 HIV infections reported to the Houston Department of Health and Human Services (HDHHS) since 1999. They also make up 17 percent of the 25,041 local AIDS cases reported to the department since the start of the epidemic in 1981.
About 200 people in NYC got false positive HIV test results. I cant imagine hearing those words. But with the continual spread of HIV throughout every community, many people do. As you would expect, getting fals HIV test results is devastating.
For patients who have access to the latest retroviral therapies, HIV is no longer the sure killer it once was. The development of drug cocktails--three-drug combinations known as highly active antiretroviral therapies (HAART)--has made it possible to keep the virus at bay. But while dozens of drugs target specific stages of HIV's life cycle, only certain combinations of drugs suppress the virus effectively.
New York City sexually transmitted infection clinics have stopped have stopped using oral fluid with OraSure Technologies' OraQuick Advance Rapid HIV 1/2 Antibody Test because of an increased rate of false positives.
When millions of HIV-infected people in poor countries began receiving advanced drug therapies, critics worried that patient care would suffer because few high-tech laboratories were available to guide treatments.
Still millions of people need HIV treatment drugs that can save their lives. World Health organization says while around 3 million HIV patients get the drugs, other millions need HIV and AIDS treatment as well.
An HIV/AIDS vaccine likely will not be available in the short term.
DSMB has determined that the experimental, once-daily antiretroviral drug regimen of emtricitabine, atazanavir and didanosine enteric-coated is inferior to a standard antiretroviral drug regimen and therefore should be discontinued in an ongoing HIV clinical trial.
Bavarian Nordic has initiated a Phase I/II clinical study with its HIV vaccine candidate: MVA-BN HIV multiantigen.
To advance underdeveloped approaches to designing a preventive HIV vaccine is launching a new program to foster the study of B cells, immune cells that can produce antibodies with the capacity to neutralize HIV.
According to HIV research a unique HIV vaccine formulation was effective in eliciting strong and balanced immune responses in healthy human volunteers.
A triple-combination therapy that includes the antiretroviral drug efavirenz is the most effective among two other widely used antiretroviral regimens at suppressing HIV viral loads for initial treatment of HIV-1 infection.
Researchers have discovered a human cell "reservoir," called follicular dendritic cells, that allows HIV to stay in an infectious state and not respond to antiretroviral drugs.
The most common HIV prevention strategies-condom promotion, HIV testing, treatment of other sexually transmitted infections, vaccine and microbicide research, and abstinence-are having a limited impact on the predominantly heterosexual epidemics found in Africa.
The "exhaustion" of immune cells that target HIV appears to result from chronic exposure to the virus, specifically exposure to the particular protein segments targeted by the pathogen-killing HIV-specific CD8 T cells.
The exclusive focus on HIV promoted by the Joint United Nations Programme on HIV/AIDS (UNAIDS) is damaging health systems and distorting health financing, and UNAIDS should be closed down immediately.
Although the overall rate of adverse events among HIV-positive people initiating antiretroviral treatment does not differ significantly among different races and genders, there are significant differences for specific adverse events.
A research group has uncovered a new route for attacking the human immunodeficiency virus (HIV) that may offer a way to circumvent problems with drug resistance.
Schering-Plough Corporation has initiated a Phase II clinical study with vicriviroc, its investigational CCR5 antagonist, for use in first-line therapy of adult treatment-naive HIV-infected patients with R5-type virus only.
Each rhesus monkey cell infected with the simian immunodeficiency virus, or SIV, produces at least 50,000 viruses over its life span, suggesting HIV spreads more rapidly than previously estimated.
Maxygen is using Monogram's Neutralizing Antibody Assay in its HIV vaccine program to rapidly and accurately screen candidate immunogens produced by gene shuffling for their ability to induce antibodies that protect against a broad range of HIV variants.